We are starting with peanut allergy which is one of the most common causes of severe and fatal allergic reactions related to food.

Our lead immunotherapy for peanut allergy, PVX108, is the first therapy designed to precisely target the root cause of this disease.

PVX108 has delivered positive results in a Phase 2 international clinical trial.

PVX108 – Peanut Allergy

PVX108 is being developed as a well tolerated, and convenient-to-use therapy to reduce the risk of allergic reactions upon accidental exposure to peanuts.

PVX108 Product Description

Composed of seven proprietary peptides. Each peptide represents one or more immuno-dominant T cell epitopes from major peanut allergens and is designed to minimize triggering acute allergic reactions during treatment. PVX108 is synthesised, characterised and manufactured to pharmaceutical quality standards.

The product does not contain whole allergens or extracts.

PVX108 Rationale

Precisely targets the T cells responsible for peanut allergy, with the aim of safely retraining the immune system to restore and maintain tolerance to peanut, to reduce the risk of allergic reactions including anaphylaxis upon accidental peanut exposure.

Patient-friendly Administration

Intradermal once per month administration. Does not require dose escalation or burdensome measures to manage risks of adverse reactions to therapy.

Clinical Status

A Phase 2, 12-month randomized double-blind, placebo-controlled safety and efficacytrial in adolescents and children with peanut allergy has been completed. An open-label 12-month extension is ongoing in children. Preparations for late-stage clinical development are underway.

PVX108 has been awarded US FDA Fast Track designation.

There are no clinical trial sites currently open for recruitment.

Learn more about our positive Phase 2 trial results Learn more about our Phase 1 clinical trial results Read our PVX108 Summary Factsheet

PVX108 is an investigational drug product
PVX108 is undergoing clinical studies to evaluate the safety and effectiveness in humans. It has not received marketing authorization or approval by any regulatory agency, including the US Food and Drug Administration, or the Australian Therapeutic Goods Administration and the European Medicines Agency.